AX3 LIFE LLC – Trademark Portfolio

Entity Type: 16

AX3 LIFE LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include AX3, AGE FEARLESSLY, and NATURE'S MOST POWERFUL ANTIOXIDANT, PERFECTED. The owner is based in Honolulu, HI.

Suite 129

2800 Woodlawn Drive

Honolulu, HI 96822

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

AX3 LIFE LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

44
Medical Services (3 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does AX3 LIFE LLC have?

AX3 LIFE LLC has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does AX3 LIFE LLC file in?

AX3 LIFE LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.

What are AX3 LIFE LLC's most well-known trademarks?

AX3 LIFE LLC's registered trademark portfolio includes well-known marks such as AX3, AGE FEARLESSLY, and NATURE'S MOST POWERFUL ANTIOXIDANT, PERFECTED. These are among 3 currently registered trademarks in the portfolio.

What is AX3 LIFE LLC's trademark registration success rate?

AX3 LIFE LLC has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.